This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Simvastatin for Treating Erectile Dysfunction (STED)

This study has been completed.
Information provided by:
Santa Casa de Porto Alegre Identifier:
First received: July 27, 2009
Last updated: September 24, 2010
Last verified: September 2010
This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac disease.It is hypothesized that the simvastatin can improve the endothelial function, improving the nitric oxide liberation in corpora cavernosa of the penis, resulting in improvement of erection.

Condition Intervention Phase
Erectile Dysfunction Vascular Disease Detected C Reactive Protein Drug: Simvastatin Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial

Resource links provided by NLM:

Further study details as provided by Santa Casa de Porto Alegre:

Primary Outcome Measures:
  • Penile erection

Enrollment: 41
Study Start Date: January 2006
Study Completion Date: December 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: Placebo
Experimental: Simvastatin
Treatment arm.
Drug: Simvastatin
simvastatin 20 daily for six months.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Erectile dysfunction
  • Elevated C reactive protein
  • Able to adhere the protocol

Exclusion Criteria:

  • Diabetes mellitus
  • Cardiac disease
  • Cerebral vascular disease
  • Hypogonadism
  • Any contraindication to simvastatin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Eduardo Touguinha Mastalir, Santa Casa de Porto Alegre Identifier: NCT00947323     History of Changes
Other Study ID Numbers: STED
Study First Received: July 27, 2009
Last Updated: September 24, 2010

Keywords provided by Santa Casa de Porto Alegre:
endothelial dysfunction
erectile dysfunction

Additional relevant MeSH terms:
Erectile Dysfunction
Vascular Diseases
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Cardiovascular Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017